<?xml version="1.0" encoding="UTF-8"?>
<p>There were six (11%) severe COVID-19 cases. They had more commonly neoplasia (
 <italic>n</italic> = 4, 67% vs. 
 <italic>n</italic> = 2, 4%; 
 <italic>P</italic> = 0.0008) among comorbidities, more commonly dyspnea (
 <italic>n</italic> = 5, 83% vs. 
 <italic>n</italic> = 5, 11%; 
 <italic>P</italic> = 0.0006) and less commonly headache (
 <italic>n</italic> = 0, 0% vs. 
 <italic>n</italic> = 28, 64%; 
 <italic>P</italic> = 0.0047) at presentation, lower median (IQR) O
 <sub>2</sub> saturation (93% (93–96) vs. 98% (96–99); 
 <italic>P</italic> = 0.0121), lower median (IQR) platelets [135 (80–163–13.04) vs. 5.93 (4.10–7.29) × 10
 <sup>9</sup>/l; 
 <italic>P</italic> = 0.0489], higher median (IQR) leukocytes (8.91 (6–51–13.04) vs. 5.93 (4.10–7.29) × 10
 <sup>9</sup>/L; 
 <italic>P</italic> = 0.0489), higher creatinine [1.45 (1.30–1.63) vs. 1.01 (0.85–1.13) mg/dl; 
 <italic>P</italic> = 0.0062], higher lactate dehydrogenase [332 (316–357) vs. 239 (172–270) U/l; 
 <italic>P</italic> = 0.0232], higher median (IQR) C reactive protein [16.99 (5.46–30.00) vs. 3.01 (0.45–10.21) mg/dl; 
 <italic>P</italic> = 0.0186], higher procalcitonin [0.72 (0.12–1.63) vs. 0.03 (0.03–0.08) ng/ml; 
 <italic>P</italic> = 0.0016], and higher ferritin [905 (595–1101) vs. 200 (84–311) ng/ml; 
 <italic>P</italic> = 0.0020]. We were unable to find any HIV or antiretroviral factors significantly associated with COVID-19 severity.
</p>
